H. Lundbeck A/S Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
H. Lundbeck A/S Stock Forecast and Price Target
According to six esteemed experts, the average price target for H. Lundbeck A/S to reach this year is kr36.50, with a potential upside of approximately 12.1%. This prediction is based on a high estimate of kr50.00 and a low estimate of kr33.00. If you want to invest in HLUN A stock, you might also want to take a look at how its competitors are doing.
12.10% Upside
H. Lundbeck A/S Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, H. Lundbeck A/S's Price has gone down from kr48.30 to kr0.00 – a 100.00% drop. Analysts predict that H. Lundbeck A/S's Fair Value will increase in the upcoming year, reaching kr66.00. This would represent an increase of 100.00%. Over the next seven years, experts predict that H. Lundbeck A/S's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$724.87 | Buy/Sell | $636.99 | 15.54% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.29 | Buy/Sell | $178.42 | 12.98% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£120.26 | Buy/Sell | £165.99 | 34.72% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF90.00 | Buy/Sell | CHF105.00 | 19.58% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF218.80 | Buy/Sell | CHF307.83 | 24.54% |
H. Lundbeck A/S Revenue Forecast for 2023 - 2025 - 2030
In the last three years, H. Lundbeck A/S's Revenue has seen an increase, rising from kr17.67B to kr19.91B. This represents a growth of 12.68%. Analysts predict that H. Lundbeck A/S's Revenue will increase in the upcoming year, reaching kr21.34B. This would represent an increase of 7.15%. According to professional forecasts, in 2030, H. Lundbeck A/S's Revenue will decrease by 13.03%, reaching kr17.32B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.26 | Buy/Sell | $32.87 | 20.74% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$269.38 | Buy/Sell | $303.65 | 17.77% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.62€ | Buy/Sell | 102.80€ | 18.97% |
.jpg)
H. Lundbeck A/S Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, H. Lundbeck A/S's Dividend per Share has fallen from kr2.50 to kr0.70 – a 72.00% decrease. In the next year, analysts believe that Dividend per Share will reach kr0.94 – an increase of 34.29%. For the next seven years, the forecast is forDividend per Share to grow by 21.43%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.70 | Buy/Sell | $58.15 | 21.92% |
| UCB Stock Forecast | UCB | Outperform |
18
|
125.10€ | Buy/Sell | 102.66€ | -0.08% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.46k | Buy/Sell | ¥2.64k | 39.18% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.25 | Buy/Sell | $11.59 | 20.75% |
| REC Stock Forecast | Recordati Industria Chimica e ... | Hold |
18
|
48.80€ | Buy/Sell | 48.61€ | 5.43% |
| 4523 Stock Forecast | Eisai | Outperform |
18
|
¥6.26k | Buy/Sell | ¥9.58k | 34.21% |
H. Lundbeck A/S EBITDA Forecast for 2023 - 2025 - 2030
H. Lundbeck A/S's EBITDA has grown in the last three years, jumping from kr4.87B to kr5.19B – an increase of 6.42%. In the next year, analysts predict that EBITDA will reach kr6.06B – an increase of 16.80%. By 2030, professionals predict that H. Lundbeck A/S's EBITDA will decrease by 23.24%, to kr3.98B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IPN Stock Forecast | Ipsen | Outperform |
17
|
112.30€ | Buy/Sell | 127.95€ | 4.19% |
| ITCI Stock Forecast | Intra-Cellular Therapies | Outperform |
10
|
$72.13 | Buy/Sell | $79.10 | 24.77% |
| GRF Stock Forecast | Grifols | Outperform |
18
|
8.09€ | Buy/Sell | 18.48€ | 134.86% |
H. Lundbeck A/S EBIT Forecast for 2023 - 2025 - 2030
In the last three years, H. Lundbeck A/S's EBIT has increased by 10.08%, going from kr2.97B to kr3.26B. In the next year, analysts are expecting an increase in EBIT, predicting it will reach kr4.54B – an increase of 39.02%. In 2030, the professionals' prediction is that HLUN A's EBIT will decrease by 23.84%, reaching kr2.49B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ORNBV Stock Forecast | Orion Oyj | Hold |
14
|
35.39€ | Buy/Sell | 42.52€ | 18.68% |
| ALKS Stock Forecast | Alkermes | Outperform |
10
|
$24.44 | Buy/Sell | $33.27 | 39.12% |
| 4506 Stock Forecast | Sumitomo Pharma | Underperform |
18
|
¥464.00 | Buy/Sell | ¥0.00 | 5.82% |
H. Lundbeck A/S EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, H. Lundbeck A/S's EPS has gone down from kr3.22 to kr0.00 – a 100.00% drop. Analysts predict that H. Lundbeck A/S's EPS will increase in the upcoming year, reaching kr4.40. This would represent an increase of 100.00%. Over the next seven years, experts predict that H. Lundbeck A/S's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£14.00 | Buy/Sell | £28.89 | 123.14% |
| ALM Stock Forecast | Almirall | Outperform |
16
|
8.47€ | Buy/Sell | 11.39€ | 29.87% |
| AQST Stock Forecast | Aquestive Therapeutics | Buy |
0
|
$3.93 | Buy/Sell | $6.33 | 129.01% |
.jpg)